Drugs / PF-04308515
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01199029 | Aug → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01101932 | Mar → Nov 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00990015 | Oct 2009 → Jan 2010 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04308515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990015 ↗ |
| Route | Oral | “Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.” NCT00990015 ↗ |